The Impact of a Methicillin-Resistant Staphylococcus Aureus Nasal Polymerase Chain Reaction Protocol on Vancomycin Length of Therapy Among Patients With Skin and Soft Tissue Infections
Journal of Pharmacy Practice · 2025
DOI: 10.1177/08971900241273175 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Anel Couzo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Vancomycin, Methicillin-Resistant Staphylococcus aureus, Soft Tissue Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objective
We evaluated the impact of a methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction (PCR) protocol on the vancomycin length of therapy (LOT) for skin and soft tissue infections (SSTIs).
Design
Retrospective quasi-experimental pre- and post- MRSA nasal PCR protocol implementation study.
Setting
Tertiary-care academic medical center in Jacksonville, Florida. Patients: Eligible patients received empiric vancomycin for SSTIs from January 1st to September 30th 2020 (pre-implementation group) and from January 1st to September 30th 2022 (post-implementation group).
Intervention
The electronic health system software was modified to provide a best-practice advisory (BPA) prompt to the pharmacist upon order verification of vancomycin for patients with SSTIs.
Methods
We reviewed patient records to determine the time from vancomycin prescription to de-escalation. The secondary outcomes were incidence of acute kidney injury (AKI), number of vancomycin levels collected, and hospital length of stay (LOS).
Results
The study included 131 patients (pre-implementation, n = 86 and post-implementation, n = 45). There was no significant difference in vancomycin length of therapy (LOT) between implementation groups: mean LOT in days and standard deviation (SD) were 2.7 (1.9) and 2.6 (1.3), respectively, p-value 0.493. Of significance, in the post-implementation group, vancomycin LOT between patients with a negative and positive MRSA PCR were 2.3 (1.1) and 3.9 (1.6), p-value 0.006. There was no difference in secondary outcomes.
Conclusion
The utilization of the MRSA nasal PCR to guide vancomycin de-escalation did not significantly change the vancomycin LOT, however in the post-implementation group there was a significant difference in vancomycin LOT between negative and positive MRSA PCRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA.
- Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, USA.
ORCID-Profile: Courtney M Willis, Kevin L Epps
Zitieren
APA
Couzo, A., Griffin, A., Willis, C. M., Mendez, J., & Epps, K. L. (2025). The Impact of a Methicillin-Resistant Staphylococcus Aureus Nasal Polymerase Chain Reaction Protocol on Vancomycin Length of Therapy Among Patients With Skin and Soft Tissue Infections. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241273175
Vancouver
Couzo A, Griffin A, Willis CM, Mendez J, Epps KL. The Impact of a Methicillin-Resistant Staphylococcus Aureus Nasal Polymerase Chain Reaction Protocol on Vancomycin Length of Therapy Among Patients With Skin and Soft Tissue Infections. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241273175
BibTeX
@article{Couzo2025,
author = {Couzo, Anel and Griffin, Adia and Willis, Courtney M and Mendez, Julio and Epps, Kevin L},
title = {The Impact of a Methicillin-Resistant Staphylococcus Aureus Nasal Polymerase Chain Reaction Protocol on Vancomycin Length of Therapy Among Patients With Skin and Soft Tissue Infections},
journal = {Journal of Pharmacy Practice},
year = {2025},
doi = {10.1177/08971900241273175}
}
EUVIMED